Embolization of Arterial Gastric Supply in Obesity

NCT ID: NCT04207424

Last Updated: 2022-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-30

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess safety and efficacy of bariatric embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles, for patients with morbid obesity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obesity is now an epidemic in the developed and developing world. Medical management is ineffective at population level. Metabolic surgery has been shown to be effective in achieving weight loss and controlling associated conditions. However, surgery is invasive and has associated complications. Furthermore, not every patient is interested in or eligible for surgery.

Bariatric gastric embolization recently emerged as a promising minimally invasive alternative to open bariatric surgery. Data from several initial pilot clinical trials suggests that gastric embolization is safe and can induce weight loss.

Previous studies have concentrated on left gastric artery embolization as the primary target vessel because it supplies the largest portion of the fundus. However, it may be desirable to target a different artery, specifically the left gastroepiploic which also supplies the fundus. The left gastric artery is spared in bariatric surgery because it supplies the residual pouch after the surgery. Embolization of the left gastric artery may result in worse healing in the event of follow-up surgery potentially excluding people should they subsequently want it or become eligible.

This study aims to assess safety and efficacy of bariatric embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles, for patients with morbid obesity.

The target population consists of adult, morbidly obese patients with contraindication for bariatric surgery. Patients included in the study will be followed up for 12 months post bariatric embolization. The primary end point is procedural safety, defined as number and severity of adverse events occurring during the study period. Secondary end points include weight loss, evolution of weight and thigh circumferences, evolution of serum ghrelin levels and evolution of quality of life indexes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Morbid Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Embolization

Patients undergoing embolization of the gastro-epiploic arcade

Group Type EXPERIMENTAL

Emblization of the gastro-epiploic arcade

Intervention Type PROCEDURE

Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Emblization of the gastro-epiploic arcade

Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient aged ≥18 and ≤ 71 years old
* BMI ≥ 40 or BMI ≥ 35 in association with one of the following comorbidities: hypertension, type 2 diabetes, obstructive sleep apnea
* Relative contraindication to bariatric surgery
* Able to sign informed consent.

Exclusion Criteria

General

* Impossible or unwilling to attend follow-up visits.
* Weight \> 250kg (weight limit of angiography table)
* Confirmed allergy to intravenous contrast agents.
* Pregnancy, breast feeding or willingness to conceive during the following year
* Impossible to maintain dorsal decubitus during intervention
* Life expectancy \< 1 year
* Current enrollment in another clinical trial
* Arterial anatomy rendering embolization very difficult or impossible (as evaluated by investigators)
* Patient under the protection of justice
* Patient under guardianship or trusteeship

Gastro-intestinal

* Pre-existing chronic abdominal pain
* History of inflammatory bowel disease
* History of gastroparesis
* History of gastric surgery, gastric embolization or radiotherapy
* History of peptic ulcer
* Significant risk factors for peptic ulcer, including daily use of non-steroidal anti-inflammatory drugs, active smoking or active infection with Helicobacter pylori
* Abnormal upper digestive endoscopy

Hepatic

* Cirrhosis
* Portal venous hypertension
* Bilirubin \> 2,0 mg/dL
* Albumin \< 2,5 g/L

Cardiovascular

* Known aortic pathology i.e. aneurysm or dissection
* Severe peripheral arterial disease

Renal

\- Renal failure, Creatinine Clearance \< 60ml/min/1,73 m2

Hematologic/Immunologic/Oncologic/Infectious

* Acute or chronic infection
* Active cancer
* Auto-immune disease requiring immunosuppression
* Neutrophil count \< 1,5 x 10 \^ 9/L
* Platelet count \< 100 x 10 \^ 9/L

Contraindication to contrast medium Visipaque solution for injection

* Hypersensitivity to the active substance (Iodixanol) or to any of the excipients
* History of immediate major or delayed skin reaction to the injection of the product
* Decompensated heart failure
* Thyrotoxicosis
* Contraindication to the use of the embogold microsphere
Minimum Eligible Age

18 Years

Maximum Eligible Age

71 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IHU Strasbourg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raoul POP, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Service de Neuroradiologie Interventionnelle, Nouvel Hôpital Civil, Strasbourg

References

Explore related publications, articles, or registry entries linked to this study.

Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA. 2008 May 28;299(20):2401-5. doi: 10.1001/jama.299.20.2401.

Reference Type BACKGROUND
PMID: 18505949 (View on PubMed)

Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health. 2007 Jul;121(7):492-6. doi: 10.1016/j.puhe.2007.01.006. Epub 2007 Mar 30.

Reference Type BACKGROUND
PMID: 17399752 (View on PubMed)

Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014 Aug 8;2014(8):CD003641. doi: 10.1002/14651858.CD003641.pub4.

Reference Type BACKGROUND
PMID: 25105982 (View on PubMed)

Baptista V, Wassef W. Bariatric procedures: an update on techniques, outcomes and complications. Curr Opin Gastroenterol. 2013 Nov;29(6):684-93. doi: 10.1097/MOG.0b013e3283651af2.

Reference Type BACKGROUND
PMID: 24100715 (View on PubMed)

Aina R, Oliva VL, Therasse E, Perreault P, Bui BT, Dufresne MP, Soulez G. Arterial embolotherapy for upper gastrointestinal hemorrhage: outcome assessment. J Vasc Interv Radiol. 2001 Feb;12(2):195-200. doi: 10.1016/s1051-0443(07)61825-9.

Reference Type BACKGROUND
PMID: 11265883 (View on PubMed)

De Wispelaere JF, De Ronde T, Trigaux JP, de Canniere L, De Geeter T. Duodenal ulcer hemorrhage treated by embolization: results in 28 patients. Acta Gastroenterol Belg. 2002 Jan-Mar;65(1):6-11.

Reference Type BACKGROUND
PMID: 12014319 (View on PubMed)

Defreyne L, Vanlangenhove P, De Vos M, Pattyn P, Van Maele G, Decruyenaere J, Troisi R, Kunnen M. Embolization as a first approach with endoscopically unmanageable acute nonvariceal gastrointestinal hemorrhage. Radiology. 2001 Mar;218(3):739-48. doi: 10.1148/radiology.218.3.r01mr05739.

Reference Type BACKGROUND
PMID: 11230648 (View on PubMed)

Goldman ML, LAND WC, Bradley EL, Anderson RT. Transcatheter therapeutic embolization in the management of massive upper gastrointestinal bleeding. Radiology. 1976 Sep;120(3):513-21. doi: 10.1148/120.3.513.

Reference Type BACKGROUND
PMID: 1085008 (View on PubMed)

Holme JB, Nielsen DT, Funch-Jensen P, Mortensen FV. Transcatheter arterial embolization in patients with bleeding duodenal ulcer: an alternative to surgery. Acta Radiol. 2006 Apr;47(3):244-7. doi: 10.1080/02841850600550690.

Reference Type BACKGROUND
PMID: 16613304 (View on PubMed)

Lang EV, Picus D, Marx MV, Hicks ME. Massive arterial hemorrhage from the stomach and lower esophagus: impact of embolotherapy on survival. Radiology. 1990 Oct;177(1):249-52. doi: 10.1148/radiology.177.1.2399325.

Reference Type BACKGROUND
PMID: 2399325 (View on PubMed)

Lieberman DA, Keller FS, Katon RM, Rosch J. Arterial embolization for massive upper gastrointestinal tract bleeding in poor surgical candidates. Gastroenterology. 1984 May;86(5 Pt 1):876-85.

Reference Type BACKGROUND
PMID: 6608465 (View on PubMed)

Ljungdahl M, Eriksson LG, Nyman R, Gustavsson S. Arterial embolisation in management of massive bleeding from gastric and duodenal ulcers. Eur J Surg. 2002;168(7):384-90. doi: 10.1080/110241502320789050.

Reference Type BACKGROUND
PMID: 12463427 (View on PubMed)

Miller M Jr, Smith TP. Angiographic diagnosis and endovascular management of nonvariceal gastrointestinal hemorrhage. Gastroenterol Clin North Am. 2005 Dec;34(4):735-52. doi: 10.1016/j.gtc.2005.09.001.

Reference Type BACKGROUND
PMID: 16303580 (View on PubMed)

Morris DC, Nichols DM, Connell DG, Burhenne HJ. Embolization of the left gastric artery in the absence of angiographic extravasation. Cardiovasc Intervent Radiol. 1986;9(4):195-8. doi: 10.1007/BF02577940.

Reference Type BACKGROUND
PMID: 3094950 (View on PubMed)

Ripoll C, Banares R, Beceiro I, Menchen P, Catalina MV, Echenagusia A, Turegano F. Comparison of transcatheter arterial embolization and surgery for treatment of bleeding peptic ulcer after endoscopic treatment failure. J Vasc Interv Radiol. 2004 May;15(5):447-50. doi: 10.1097/01.rvi.0000126813.89981.b6.

Reference Type BACKGROUND
PMID: 15126653 (View on PubMed)

Rosch J, Dotter CT, Brown MJ. Selective arterial embolization. A new method for control of acute gastrointestinal bleeding. Radiology. 1972 Feb;102(2):303-6. doi: 10.1148/102.2.303. No abstract available.

Reference Type BACKGROUND
PMID: 4536688 (View on PubMed)

Schenker MP, Duszak R Jr, Soulen MC, Smith KP, Baum RA, Cope C, Freiman DB, Roberts DA, Shlansky-Goldberg RD. Upper gastrointestinal hemorrhage and transcatheter embolotherapy: clinical and technical factors impacting success and survival. J Vasc Interv Radiol. 2001 Nov;12(11):1263-71. doi: 10.1016/s1051-0443(07)61549-8.

Reference Type BACKGROUND
PMID: 11698624 (View on PubMed)

Toyoda H, Nakano S, Takeda I, Kumada T, Sugiyama K, Osada T, Kiriyama S, Suga T. Transcatheter arterial embolization for massive bleeding from duodenal ulcers not controlled by endoscopic hemostasis. Endoscopy. 1995 May;27(4):304-7. doi: 10.1055/s-2007-1005697.

Reference Type BACKGROUND
PMID: 7555935 (View on PubMed)

Kipshidze N, Archvadze A, Bertog S, Leon MB, Sievert H. Endovascular Bariatrics: First in Humans Study of Gastric Artery Embolization for Weight Loss. JACC Cardiovasc Interv. 2015 Oct;8(12):1641-4. doi: 10.1016/j.jcin.2015.07.016. No abstract available.

Reference Type BACKGROUND
PMID: 26493259 (View on PubMed)

Syed MI, Morar K, Shaikh A, Craig P, Khan O, Patel S, Khabiri H. Gastric Artery Embolization Trial for the Lessening of Appetite Nonsurgically (GET LEAN): Six-Month Preliminary Data. J Vasc Interv Radiol. 2016 Oct;27(10):1502-8. doi: 10.1016/j.jvir.2016.07.010. Epub 2016 Aug 24.

Reference Type BACKGROUND
PMID: 27567998 (View on PubMed)

Weiss CR, Akinwande O, Paudel K, Cheskin LJ, Holly B, Hong K, Fischman AM, Patel RS, Shin EJ, Steele KE, Moran TH, Kaiser K, Park A, Shade DM, Kraitchman DL, Arepally A. Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity Trial. Radiology. 2017 May;283(2):598-608. doi: 10.1148/radiol.2016160914. Epub 2017 Feb 14.

Reference Type BACKGROUND
PMID: 28195823 (View on PubMed)

Bai ZB, Qin YL, Deng G, Zhao GF, Zhong BY, Teng GJ. Bariatric Embolization of the Left Gastric Arteries for the Treatment of Obesity: 9-Month Data in 5 Patients. Obes Surg. 2018 Apr;28(4):907-915. doi: 10.1007/s11695-017-2979-9.

Reference Type BACKGROUND
PMID: 29063494 (View on PubMed)

Pirlet C, Ruzsa Z, Costerousse O, Nemes B, Merkely B, Poirier P, Bertrand OF. Transradial left gastric artery embolization to treat severe obesity: A pilot study. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):365-370. doi: 10.1002/ccd.27846. Epub 2018 Oct 4.

Reference Type BACKGROUND
PMID: 30286527 (View on PubMed)

Elens S, Roger T, Elens M, Rommens J, Sarafidis A, Capelluto E, Delcour C. Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety. Cardiovasc Intervent Radiol. 2019 Apr;42(4):513-519. doi: 10.1007/s00270-018-2130-x. Epub 2018 Nov 28.

Reference Type BACKGROUND
PMID: 30488305 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19-005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Endoscopic Sleeve Gastroplasty
NCT02948621 COMPLETED
Endoscopic Gastric Tubulization
NCT03554902 RECRUITING